title: Effectiveness of sequential use of biologics in the treatment of moderate to severe psoriasis in real world Canadian academic clinical practice: A cohort study.
authors.affiliation: Faculty of Medicine, University of Toronto, Ontario, Canada.
authors.forename: Judy K
authors.initials: JK
authors.lastname: Qiang
authors.affiliation: School of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
authors.forename: Ali
authors.initials: A
authors.lastname: Shahbaz
authors.affiliation: Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
authors.forename: Whan
authors.initials: W
authors.lastname: Kim
authors.affiliation: Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
authors.forename: Joseph
authors.initials: J
authors.lastname: Marinas
authors.affiliation: Dalla Lana School of Public Health, University of Toronto, Ontario, Canada.
authors.forename: Simon
authors.initials: S
authors.lastname: Greaves
authors.affiliation: Divison of Dermatology, Department of Medicine, University of Toronto, Ontario, Canada. Electronic address: jensen.yeung@utoronto.ca.
authors.forename: Jensen
authors.initials: J
authors.lastname: Yeung
mesh_terms: D000046:Academic Medical Centers; D000068879:Adalimumab / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001688:Biological Products / Q000627:therapeutic use*; D002170:Canada; D015331:Cohort Studies; D003879:Dermatologic Agents / Q000627:therapeutic use*; D057915:Drug Substitution / Q000379:methods*; D000068800:Etanercept / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy*; D012189:Retrospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D017211:Treatment Failure; D016896:Treatment Outcome; D000069549:Ustekinumab / Q000627:therapeutic use
chemical_list: D001688:Biological Products; D003879:Dermatologic Agents; D000069285:Infliximab; D000069549:Ustekinumab; D000068879:Adalimumab; D000068800:Etanercept